Finance

Lists
688513:SHA
Chengdu Easton Biopharmaceuticals Co Ltd
CN¥46,08
+0,04%
(+0,020) 1D
15 Okt., 11:29:49 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688513...
Open
CN¥45,30
High
CN¥46,55
Low
CN¥45,02
Mkt. cap
8,15 mjd
Avg. vol.
1,91 m
Volume
763,62 k
Dividend
1,06%
Quarterly dividend
CN¥0,12
Ex-dividend date
02 Jun. 2026
P/E ratio
28,78
52-wk high
CN¥80,48
52-wk low
CN¥40,25
EPS
CN¥1,60
No. of employees
1 k
Open
CN¥45,30
High
CN¥46,55
Low
CN¥45,02
Mkt. cap
8,15 mjd
Avg. vol.
1,91 m
Volume
763,62 k
Dividend
1,06%
Quarterly dividend
CN¥0,12
Ex-dividend date
02 Jun. 2026
P/E ratio
28,78
52-wk high
CN¥80,48
52-wk low
CN¥40,25
EPS
CN¥1,60
No. of employees
1 k
News stories
From web sources and news partners
About Chengdu Easton Biopharmaceuticals Co Ltd
CEO-
Employees1,42 k
Founded01 Jun. 2009
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
364,69 m
312,26 m
326,26 m
332,64 m
Cost of goods sold
87,18 m
88,47 m
73,62 m
82,94 m
Cost of revenue
87,18 m
88,47 m
73,62 m
82,94 m
Research and development expenses
54,95 m
79,44 m
72,66 m
77,99 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
136,71 m
128,80 m
143,86 m
107,14 m
Operating expense
197,59 m
214,09 m
212,02 m
195,99 m
Total operating expenses
284,77 m
302,56 m
285,64 m
278,93 m
Operating income
79,91 m
9,70 m
40,62 m
53,71 m
Other non operating income
-228,90 k
230,85 k
-519,09 k
493,27 k
EBT including unusual items
92,35 m
57,56 m
47,40 m
86,84 m
EBT excluding unusual items
79,77 m
51,53 m
41,48 m
54,72 m
Income tax expense
8,76 m
4,15 m
4,12 m
18,02 m
Effective tax rate
9,49%
7,21%
8,69%
20,75%
Other operating expenses
4,49 m
8,00 m
-4,46 m
11,52 m
Net income
83,59 m
63,90 m
50,83 m
78,92 m
Net profit margin
22,92%
20,46%
15,58%
23,73%
Earnings per share
-
-
-
-
Interest and investment income
733,65 k
42,65 m
1,95 m
2,46 m
Interest expense
-615,69 k
-622,07 k
-575,93 k
-792,69 k
Net interest expenses
117,96 k
42,02 m
1,38 m
1,67 m
Depreciation and amortization charges
-
-
-
-
EBITDA
100,25 m
32,44 m
63,37 m
81,43 m
Gain or loss from assets sale
-
-29,35 k
-
-18,53 k
AI content may include mistakes. Learn more
Google-programme